Routine compliance certificate on securities dematerialization for Apr-Jun 2026
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medicamen Biotech filed a routine compliance certificate under SEBI Regulation 74(5) for the quarter ended June 30, 2026. Registrar MUFG Intime India confirmed that securities received from depository participants for dematerialization during the quarter were processed, listed on the stock exchanges, and the certificates were mutilated and cancelled with the depository name substituted in the register of members within the required 30-day timeline. No changes to share capital or ownership.
No impact on shareholders. This is a standard procedural filing required by SEBI with no business or price implications.